Guidance for Industry and Food and Drug Administration Staff: Mobile Medical Applications

September 3, 2015
The Food and Drug Administration (FDA) recognizes the extensive variety of actual and potential functions of mobile apps, the rapid pace of innovation in mobile apps, and the potential benefits and risks to public health represented by these apps. The FDA is issuing this guidance document to inform manufacturers, distributors, and other entities about how the FDA intends to apply its regulatory authorities to select software applications intended for use on mobile platforms (mobile applications or “mobile apps”). Given the rapid expansion and broad applicability of mobile apps, the FDA is issuing this guidance document to clarify the subset of mobile apps to which the FDA intends to apply its authority.
Previous
Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims
Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims

This guidance describes how the Food and Drug Administration (FDA) reviews and evaluates existing, modified...

Next
A Review of Patient Reported Outcome Labels in the U.S. - 2006-2013
A Review of Patient Reported Outcome Labels in the U.S. - 2006-2013

<p>Recorded Live May 15, 2014</p> <p>Analysis of PRO Evidence for Orphan Drug Label Claims</p>